Skip to main content

New Indiana Cardiology Institute to Use IU s Genomic, Proteomic Resources

NEW YORK, March 22 (GenomeWeb News) - A new public/private non-profit organization will use the genomic and proteomic research facilities at the Indiana University School of Medicine to conduct heart disease studies, BioCrossroads, which co-founded the entity with IU, said yesterday.


The organization, called the Fairbanks Institute, will coordinate a long-term health study integrating patient data to focus efforts on heart disease prevention and treatment. It will focus on other diseases as well, with the help of a $10 million start-up donation from the Fairbanks Foundation.


The institute will take advantage of Indiana University's genomic and proteomic divisions and of the Indiana Genomics Initiative, according to a statement.


It will also collaborate with the public-private collaboration BioCrossroads and with the Regenstrief Institute.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.